911-65-9

Basic information

• Product Name: etonitazene
• Synonyms: etonitazene;1-[2-(Diethylamino)ethyl]-2-(p-ethoxybenzyl)-5-nitro-1H-benzimidazole;ARC-1G-2;Ciba-20684BA;Etonitazine;NIH-7607;2-[2-(4-ethoxybenzyl)-5-nitro-benzimidazol-1-yl]ethyl-diethyl-amine;2-[2-[(4-ethoxyphenyl)methyl]-5-nitro-benzimidazol-1-yl]-N,N-diethyl-ethanamine
• CAS NO: 911-65-9
• Molecular Formula: C₂₂H₂₈N₄O₃
• Molecular Weight: 396.4827
• EINECS: 213-009-1
• Mol File: 911-65-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 580.7 °C at 760 mmHg
• Flash Point: 305 °C
• Appearance: /
• Density: 1.17g/cm³
• Vapor Pressure: 1.78E-13mmHg at 25°C
• Refractive Index: 1.591
• PKA: 9.90±0.25(Predicted)
• CAS DataBase Reference: etonitazene(CAS DataBase Reference)
• NIST Chemistry Reference: etonitazene(911-65-9)
• EPA Substance Registry System: etonitazene(911-65-9)

Safety Data

• Hazardous Substances Data: 911-65-9(Hazardous Substances Data)

Usage

Description

Etonitazene (Item No. 21824) is an analytical reference standard categorized as an opioid. Etonitazene is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.

InChI:InChI=1/C22H28N4O3/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3/h7-12,16H,4-6,13-15H2,1-3H3

Upstream product

• 97-00-7 1-chloro-2,4-dinitro-benzene 
• 100-36-7 N,N-diethylethylenediamine 
• 56223-91-7 N’-(2,4-dinitrophenyl)-N,N-diethylethane-1,2-diamine 
• 5099-39-8 N⁽¹⁾-(2-(diethylamino)ethyl)-4-nitrobenzene-1,2-diamine 
• 55154-71-7 N-[2-{(2-(diethylamino)ethyl)amino}-5-nitrophenyl]-2-(4-ethoxyphenyl)acetamide 

Downstream Products

• 75821-80-6 1-[2-(diethylamino)ethyl]-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-amine 
• 925216-79-1 2-(4-ethoxybenzyl)-1-(1-methylpiperidin-4-yl)-5-nitro-1H-benzo[d]imidazole 
• 925216-51-9 N-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)thiophen-2-carboximidamide 
• 925216-80-4 N-(2-(4-ethoxybenzyl)-1-(1-methylpiperidin-4-yl)-1H-benzo[d]imidazol-5-yl)thiophen-2-carboximidamide 
• 925216-58-6 N-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)furan-2-carboximidamide 
• 925216-65-5 N-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)thiophen-3-carboximidamide 
• 925216-60-0 N-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)furan-3-carboximidamide 
• 925216-54-2 N-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)acetimidamide 
• 925216-62-2 1-(1-(2-(diethylamino)ethyl)-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-yl)-3-nitroguanidine 

Relevant articles and documents

Synthesis and molecular docking for antiinflammatory studies of 2-(arylmethyl)-1-ethyl-1H-benzo[d]imidazol-5-amines

1-Chloro-2,4-dinitrobenzene (1) was reacted with aliphatic amines (2) in ethanol as solvent under reflux condition for 16-24 h to form N-alkyl-2,4-dinitroaniline (3). Compound 3 undergoes reduction to from N-alkyl-4-nitrobenzene-1,2-diamine (4). Compound 4 was treated with carboxylic acid (5) to offered N-(2-(alkylamino)-5-nitrophenyl)-2-arylacetamide (6) which on cyclization gave 2-(arylmethyl)-1-ethyl-5-nitro-1H-benzo[d]imidazole (7). Finally, compound 7 undergoes reduction give 2-(arylmethyl)-1-ethyl-1H-benzo[d]imidazol-5-amine (8). The synthesized compounds were characterized by using spectral analyses. The compounds synthesized were confirmed by spectral analyses. Molecular docking of 5COX with the ligand using docking server, predicted the compound to be a potential anti-inflammatory compound.

Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity

The present invention relates to benzimidazole compounds having dual nitric oxide synthase (NOS) inhibitory activity and agonist activity at the mu-opioid receptor, to pharmaceutical and diagnostic compositions containing them, and to their medical use, particularly as compounds for the treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain.